I have never seen a fall this quickly. It did not even remotely do this on the vastly disastrous previous RS. Still for a fact if we were already in bankruptcy court, over all that was worse for some. I for instance sold at .135 on the July warning. Others sold at different points later, still doing okay on a relative basis.
I will concede that going back to 2016 convertible financing deal could be argued as unethical. But where do you draw the line? A good case could be made that the day delcath first went public, it was unethical. The biotech game is fraught with difficulty.